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with usual activities and 23.6% of patients with mobility. Visual Analogue Scale 
(VAS) QoL scores for quiescent and active UC patients were 78.41 (14.89) and 69.50 
(19.41) (p= 0.0205), respectively. Quiescent patients had insignificantly better scores 
in all SIBDQ elements (global, systemic, social, bowel, emotional), global scores for 
patients with quiescent and active UC were 5.08 (1.31) and 4.75 (1.26) respectively. 
WPAI:UC indicated high levels of unemployment (40.7%). On average: work time 
missed (12.25% (27.30)), impairment while working (20.46% (25.85)) and overall work 
impairment (26.47% (32.21)). Scores for impairment of non-work activity for quies-
cent and active patients were 17.10% (25.45) and 27.39% (28.62) (p= 0.0244), respec-
tively. ConClusions: Patients with active UC demonstrated lower QoL measured 
by VAS and greater impairment of non-work activities. UC patients experienced a 
high percentage of unemployment and significant productivity loss.
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objeCtives: Introduced in 2006 in England, the Better Care, Better Value (BCBV) indi-
cators aim to promote cost-effective prescribing in the NHS. Previous data presented 
at ISPOR showed that the total cost of statin prescriptions fell by 44% between 2007 
and 2012, and that much of this decrease was likely attributable to the prescription 
of generic atorvastatin following patent expiry of the proprietary form. This analysis 
aimed to evaluate patterns of proprietary prescribing of proton pump inhibitors (PPIs), 
another category of drugs identified by the BCBV indicators. Methods: Prescription 
Cost Analysis databases were reviewed (2007–2012). Data extracted were the number 
of prescription items dispensed yearly in the community in England for 5 commonly 
prescribed PPIs, the preparation class and net ingredient cost (NIC) of each item. 
The overall NIC (sometimes used as a proxy of budget impact to the NHS) for PPIs 
and the proportion of proprietary items prescribed each year for each drug were 
compared. Results: Between 2007 and 2012 the total NIC of PPIs decreased by 38%. 
Over the same period, the decrease in the proportion of proprietary prescriptions was 
greater for PPIs (78%) than previously reported for statins (65%); however, this did not 
translate into a greater saving in total NIC. This could be due to the higher average 
number of prescriptions per year and the higher average NIC per prescription item 
for statins than for PPIs. Analysing data for each PPI, we found dramatic decreases 
in proprietary prescribing (100% to < 11%) within two years following patent expiry 
of the proprietary form. ConClusions: There was a decrease in the proportion of 
proprietary prescribing of PPIs in England between 2007 and 2012, with rapid declines 
following patent expiry of proprietary drugs. This suggests that the BCBV indicator is 
being met for PPIs as well as for statins.
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objeCtives: IBD-specific quality measures calling for the use of steroid sparing regi-
mens (i.e., those involving anti-TNFs and non-biologic immunomodulators) were 
recently adopted by the Center for Medicare and Medicaid Services (CMS). However, 
many older patients have contraindications to anti-TNFs. Our objective was to 
describe drug utilization and patient characteristics among older IBD patients with 
anti-TNF contraindications. Methods: A retrospective cohort study was conducted 
using CMS’ national 5% sample for 2006-2009 including Medicare patients with ≥ 12 
months Parts A and B, ≥ 6 months Part D, an IBD diagnosis (≥ 2 claims for ICD-9CM 
555.xx or 556.xx) and contraindications to anti-TNFs (advanced CHF, malignancies). 
We described the prevalence and days of exposure to each IBD drug class. Patient 
characteristics associated with steroid exposure were examined using a negative 
binomial-logit hurdle model. Results: Among 10,362 patients, 18% (n= 1860; 53% 
CHF, 39% malignancy, 8% both CHF and malignancy) had contraindications to anti-
TNF therapy. The mean age was 79 years, 67% were female and 87% white. Steroid 
use ranged from 258-283 users per 1000 patients per year and averaged 123-145 mean 
annual treatment days for utilizers. Anti-TNFs and non-biologic immunomodula-
tors were used infrequently (anti-TNFs: 19-30 users per 1000 patients each year, 
non-biologic immunomodulators: 29-36 users per 1000 patients each year). Patients 
who were younger, white, receiving any IBD drug class except anti-TNFs, had poly-
pharmacy, more hospitalizations or absence of stroke history had greater odds of 
receiving steroids. Among steroid recipients, polypharmacy and anti-TNF use were 
associated with a 65% (23%-121%) and 79% (28%- 150%) greater number of steroid 
therapy days, respectively. ConClusions: Use of steroids exceeded steroid sparing 
regimens supporting the importance of the new quality measure as a strategy to 
improve care. Patients with anti-TNF contraindications are frequently appropriate to 
receive non-biologic immunomodulators and our findings suggest that these drugs 
are underutilized in this cohort.
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objeCtives: To assess the predictive value of patient-reported stool frequency and 
rectal bleeding for mucosal healing based on endoscopic evaluation in patients 
with active UC. Methods: Patients with active UC defined by a Mayo score of 6-12 
including an endoscopy subscore of ≥ 2 were randomized to receive placebo or goli-
mumab (GLM) 200mg/100mg or 400mg/200mg at weeks 0 and 2, respectively. Patient-
reported stool frequency and rectal bleeding from weeks 0 through week 6 were 
collected from the most recent consecutive 3-day period within the 2 weeks prior to 
the visit. Responder was defined as normalized stool frequency or no rectal bleeding. 
Mucosal healing is defined as an endoscopy subscore of the Mayo score of 0 or 1. 
Odds Ratio (OR), positive predictive value (PPV) and likelihood Ratio Positive (LR+) 
were estimated for predicting mucosal healing using normalized stool frequency 
or no rectal bleeding. Receiver Operating Characteristic (ROC) curve was developed 
based on different cut-off of combined stool frequency and rectal bleeding scores 
(0-6). Results: At week 0, 99% of patients reported abnormal stool frequency and 
86.9% reported rectal bleeding. Among patients who reported no rectal bleeding 
at week 6, 66.5% achieved mucosal healing compared to 16.0% of patients with 
rectal bleeding (OR= 9.9, p< 0.001, PPV= 0.65, LR= 3.0). Similarly, among patients with 
normalized stool frequency at week 6, 77.1% achieved mucosal healing vs. 32.8% % 
of patients with abnormal stool frequency at week 6 (OR= 6.9, p< 0.001, PPV= 0.77, 
LR= 5.3). On ROC curve, a cut-off of ≤ 2 on a combined stool frequency and rectal 
bleeding score resulted in a sensitivity of 85% and specificity of 70.6% for predicting 
mucosal healing at Week 6. ConClusions: Normalized stool frequency and no 
rectal bleeding are predictors for mucosal healing in patients with UC.
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objeCtives: To examine correspondences between PROs with changes in disease 
activity and treatment in patients with UC. PRO instruments assessed generic health-
related quality of life (HRQL; 12-item Short Form v2 [SF-12v2]), disease-specific HRQL 
(Shortened Inflammatory Bowel Disease Questionnaire [SIBDQ]), and work-related 
outcomes (WROs; Work Productivity and Activity Impairment Questionnaire: UC 
[WPAI:UC]). Methods: Adults with mild-to-moderate UC received MMX mesala-
mine 4.8 mg/d for 8 weeks in an open-label, prospective study (NCT01124149). PROs, 
and a modified UC-Disease Activity Index (UCDAI) that captured several symptoms, 
including stool frequency (SF) and rectal bleeding severity (RBS), were administered at 
baseline and Week 8. Spearman coefficients examined associations between changes 
in PROs and disease activity. Analysis of variance (ANOVA) models tested changes in 
scores over time, with Cohen’s d’s used to interpret effect sizes. ANOVAs examined 
PRO change scores as a function of improvement (≥ 1-point reduction) in SF and 
RBS. Results: 639 patients completed treatment. Change scores at Week 8 were 
large for SIBDQ (mean d = 0.93; range: 0.78, 1.16) and medium-to-large for SF-12v2 
(0.70; 0.52, 0.88) and WPAI:UC (–0.74; –0.34, –0.93). Changes in UCDAI total scores cor-
related most strongly with SIBDQ (average correlation = –0.41), followed by WPAI:UC 
(0.38) and SF-12v2 (–0.34). RBS improvement corresponded most strongly to SIBDQ 
(average d = 0.47) compared with SF-12v2 (0.41) and WPAI:UC (–0.38). SF improvement 
corresponded most strongly to WPAI:UC (average d = –0.67) versus SIBDQ (0.61) and 
SF-12v2 (0.58). ConClusions: Disease-specific HRQL showed greatest sensitivity to 
treatment and strongest response to improvements in RBS compared with generic 
HRQL or WROs. However, WROs showed the largest improvements in concordance 
with SF. PROs were more responsive to changes in SF than RBS. Results indicate that 
different PRO instruments, capturing different constructs, are sensitive to varying 
aspects of treatment-related improvements in UC disease activity.
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objeCtives: Ulcerative colitis (UC) is a chronic disabling condition associated with 
reduced quality of life (QoL). Little data exists on differences between patients with 
active versus quiescent UC regarding QoL and productivity loss. Methods: Patients 
with moderate/severe UC (Mayo score ≥ 6), ≥ 18 years who received conventional 
therapies during the previous year were recruited in Belgium, France, Germany, 
Greece, Italy, The Netherlands, Spain, Sweden, Switzerland, Turkey, and UK. Patients 
who received biologics, colectomy or ileo-anal J-pouch reconstruction were 
excluded. Patients were classified with quiescent or active UC; quiescence being 
clinical Mayo score ≤ 2, no sub-score> 1, no corticosteroids for two months or, if no 
endoscopy, partial Mayo score ≤ 2, no corticosteroids for two months. Patients com-
pleted EQ-5D-5L, Short Inflammatory Bowel Disease (SIBDQ) and Work Productivity 
Activity Impairment:UC (WPAI:UC) questionnaires. Quiescent and active patients 
were compared using chi-square and t-test. Results: 253 patients were included, 
mean (SD) age 46.6(16.2) years, 59% male, 250 patients completed questionnaires, 
218 (86%) had active UC. EQ-5D-5L indicated that 39.0% of patients had problems 
